A pilot exploration to Posiphen to normalize amyloid precursor protein in Down syndrome

Xu-Qiao Chen

Down syndrome (DS) pathology: DS is the most common cause of Alzheimer’s disease (AD) and has a known AD-causing genetic variation which is trisomy of the whole or part of Homo sapiens chromosome 21 (HSA21) (Chen and Mobley, 2019a). Compared with AD, DS usually present with various symptoms and manifestations which are related to dysfunction of multiple body systems; the extra copies of the many genes present in HSA21 in DS can cause various developmental problems including neurodevelopmental defects, which underline the physical features in DS and may contribute to the AD-related neurological symptoms of DS like cognition decline (Antonarakis et al., 2020). However, DS and AD share many pathological hallmarks including amyloid plaques and neurofibrillary tangles, synaptic and neuronal loss, dysregulation of endosomal pathway and others (Chen and Mobley, 2019a). The plaques and tangles have been studied extensively, while the dysfunction of early endosome has been found to be impacted long before appearance of amyloid deposits and neurofibrillary tangles with amyloid beta (Aβ) of varying length and phosphorylated tau as the main components, respectively (Nixon, 2017; Chen and Mobley, 2019a). Deficient endosome-mediated retrograde axonal transport of neurotrophic signals plays an important role in the neuropathogenesis in both DS and AD as continuing neurotrophic support is required for maintenance of mature neurons including the basal forebrain cholinergic neurons (BFCNs) whose degeneration has been linked to age-related cognitive dysfunction in DS and AD (Chen and Mobley, 2019b). HSA21 contains about 233 protein-coding genes with several encoding protein products demonstrated to contribute to different phenotypes in DS (Antonarakis et al., 2020) from the extensive researches in the different mouse models of DS, including Ts65Dn mouse which are segmentally trisomic for orthologs of about half of the protein coding genes located on HSA21 (Antonarakis et al., 2020). Accumulated evidence have attributed AD pathogenesis to toxic oligomeric Aβ and tau (Chen and Mobley, 2019a), however, recent clinical trials intending to target them in AD have yet to demonstrate considerable efficacy. Importantly, the 99 amino acid C-terminal fragment (β-CTF) of amyloid precursor protein (APP) was recently found to dysregulate endosomal and lysosomal systems as well as induce cholinergic neurodegeneration in an Aβ-independent manner (Xu et al., 2016; Nixon, 2017; Chen and Mobley, 2019b). Thus, reviewing the hypotheses for AD and discovering novel targets will be beneficial to combat AD and AD in DS.

APP contribution to AD in DS: APP as a type 1 transmembrane protein is processed by sequential cleavage via either β- or α-secretase to produce the C-terminal fragments, β-CTF or α-CTF, respectively. The former is then cleaved by γ-secretase to yield the APP intracellular domain (AICD) and Aβ peptides of varying length while cleavage of the latter yields the same AICD and the P3 peptide (Chen and Mobley, 2019a).

Multiple studies using APP knockdown in cell culture, in the Ts65Dn mouse, in which APP gene copy number was reduced to two in Ts65Dn, and using APP/β-CTF overexpression all support the contribution of increased APP gene dose in inducing early endosome enlargement phenotypes (Salehi et al., 2006; Xu et al., 2016). Importantly, increased APP gene dose in Ts65Dn mice markedly induced axonal transport of nerve growth factor signaling and caused neurodegeneration of BFCNs (Salehi et al., 2006). Further studies showed that APP/β-CTF-induced Rab5 hyperactivation and early endosome enlargement were linked to the aberrant retrograde axonal transport of neurotrophin signals (Xu et al., 2016). Definitely increased APP gene dose has effects beyond changes in early endosome that may also contribute to neurodegeneration, however, these data strongly support dysregulation of early endosome system along with deficits in neurotrophin signal transduction is linked to degenerations of many neuron populations including BFCNs. It is reasonable to speculate that the cumulative effect over decades of gradually disrupted neurotrophin signaling contributes significantly to neurodegeneration (Chen and Mobley, 2019b). Although APP and Aβ peptide have been shown to cause tau pathology, using CRISPR/Cas9 approach, normalization of APP gene dose to two in DS induced pluriotent stem cell (iPSC)-derived cortical neurons was reported to reduce both Aβ, and APP42/40 ratio, but fail to affect increased tau phosphorylation (Ovchinnikov et al., 2018). As the protein products of other triplicated genes on HSA21 have also been shown to contribute tau hyperphosphorylation in DS context (Antonarakis et al., 2020), whether or not and to what extent APP is related to tau pathology in DS need further elucidation.

In addition, recently β-CTF was shown to mediate APP-induced lysosomal dysfunction through affecting either expression/mutation or activity of lysosomal enzymes (Jiang et al., 2019). The direct evidence for an essential role of APP in AD appearance in DS was from two rare cases of DS subjects who are partial trisomy 21 that is lacked triplication of APP. They are clinically devoid of AD confirmed by several assessments (Prasher et al., 1998; Doran et al., 2017). Thus targeting full length APP (fl-APP) itself becomes an alternative strategy to combat AD pathology in DS and possibly also in AD. This strategy is based on the vast findings supporting the APP gene dose hypothesis. Although APP was shown to contribute to several pathologies, whether or not it is feasible to manipulate APP expression in DS with AD in vivo to reverse the pathological phenotypes needs to be explored and tested.

APP-targeting strategy: starting with Posiphen: Based on the preclinical studies on the roles of APP in the pathogenesis of AD in DS, several strategies can be envisioned. APP expression can be modulated on the levels of either mRNA or protein. Among them we started to test our hypothesis that normalizing APP protein can rescue AD-relevant endosomal phenotype in Ts65Dn mice (Chen et al., 2020). Posiphen is an orally available small molecule that targets a conserved regulatory element (iron-response element stem loop) in the mRNAs of several proteins including APP and reduces their translation. Posiphen has been found to decrease fl-APP levels as well as its processing products in several cell lines as well as in AD mouse models. It is noted that Posiphen reduced the levels of APP and its secreted products, and normalized impairments in spatial working memory, contextual fear learning and synaptic function in the APP/PS1 mouse model of AD (Teich et al., 2018). Importantly, in a Phase I clinical trial Posiphen was proved to be well tolerated and induced reduction in the levels of soluble APP fragments and tau species in the cerebrospinal fluid of mild cognitive impairment subjects (Macccechini et al., 2012).

We found that in vitro Posiphen lowered fl-APP and CTFs in a translation-dependent manner, reversed Rab5 hyperactivation and early endosome enlargement and restored retrograde axonal transport of neurotrophin signaling in Ts65Dn primary neurons. In vivo, Posiphen treatment (50 mg/kg/d, 26 days, intraperitoneal delivery) of 16 month-old Ts65Dn mice was also well tolerated and resulted in normalization of the levels of fl-APP, CTFs and induced a reduction in Aβ1-42, reduced Rab5 activity, phosphorylated tau, and more importantly reversed deficits in the activation of tropomyosin receptor kinase B/mitogen-activated protein kinase/CAMP response element-binding protein signaling pathways (Figure 1). Choline acetyltransferase (ChAT) is expressed in cholinergic neurons and dysfunction of the cholinergic system contributes to the pathogenesis of AD in DS (Chen and Mobley, 2019b). Posiphen treatment also restored the ChAT levels in Ts65Dn mice to that in normal euploid (2N) mice (Chen et al., 2020). These results provide further evidence supporting the APP gene dose hypothesis and also the theoretical basis for the application of APP-targeting strategy to combat the AD-related pathologies in DS.

In addition to Posiphen, other methods intending to reduce the levels of APP mRNA (e.g., antisense oligonucleotides (ASOs)) and the translation of APP mRNA (e.g., miRNAs) can also be considered (Chen et al., 2020) (Figure 1). Especially the ASO strategy is promising, as ASO has displayed amazing effects to reduce or modify toxic protein expression and enabled clinical trials to treat neurodegenerative diseases including Huntington disease, amyotrophic lateral sclerosis and Parkinson’s disease (Leavitt and Tabrizi, 2020).
APP++–

Posiphen reverses the endosome-related pathologies in the Ts65Dn mouse model of DS. In the brains of Ts65Dn mouse, due to increased App gene dose, there are increased APP mRNA and protein levels of fl-APP along with its processing products including c-CTF, β-CTF and Aβ peptide species. Increased levels of β-CTF can lead to Rab5 hyperactivation and abnormal early endosome enlargement. Ablation in early endosome may contribute to the deficits in the retrograde axonal transport of neurotrophic signaling in several neuron populations including BFCNs and cortical neurons thus compromising their trophic support for these neurons and leading to neuronal degeneration especially the vulnerable BFCNs. Posiphen treatment can reduce the translation of APP mRNA and normalize the protein levels of fl-APP both in vitro and in vivo, thus correcting the majority of its downstream products including CTFs and Aβ. Consistently, Posiphen treatment also reversed Rab5 hyperactivation and early endosome enlargement induced by APP/β-CTF, and restored the retrograde transport of neurotrophin and neurotrophic signal transduction. It should be noted that in vivo Posiphen also normalized the levels of both phosphorylated tau and Chat protein whose dysregulation contribute to the pathogenesis of DS. Furthermore, supporting the biological effects of Posiphen in DS, thus, Posiphen rescued the endosomal pathologies in Ts65Dn mouse through normalizing the protein levels of fl-APP and its processing products. Whether or not Posiphen treatment can correct the abnormal behaviors especially those related to cognitive function needs further elucidation. In addition to Posiphen, other strategies including ASO and miRNA against APP mRNA could be also envisioned to achieve the same goal of normalizing fl-APP levels in DS. Aβ: Amyloid beta; APP: amyloid precursor protein; ASO: antisense oligonucleotide; BFCN: basal forebrain cholinergic neuron; Chat: choline acetyltransferase; CTF: C-terminal fragment; DS: Down syndrome; fl-APP: full-length amyloid precursor protein.

Limitations and perspective: Although Posiphen has been shown to reverse AD-related early endosome phenotypes in Ts65Dn mice, we failed to rescue the cholinergic neuron numbers and deficits in behavior assessments including Y-maze, open field and nest building (Chen et al., 2020). Actually, older mice of both 2N and Ts65Dn showed worse performance compared to younger mice in behavior tests like Y-maze, thus age is a possible limiting factor to demonstrate a positive reflection after Posiphen treatment in mouse models. Considering the age of Ts65Dn mice used in our study, we speculate that young animals with treatment for longer periods are needed in combination with sensitive markers to assess the potential protection of Posiphen or other APP-targetting strategies against cholinergic dysfunction and deficient behaviors especially those related to cognitive function. However, our findings motivated renewed attention to how APP and its processing products drive AD-related pathologies in DS and consideration of evaluating Posiphen in clinical trials in DS both with and without AD.

Whether or not it is feasible to reverse the other pathologies induced by the year-long increase in DS, further studies of APP and its processing products are needed. As DS demonstrate AD pathology by 40 years old and dementia by about age 60 years (Chen and Mobley, 2019a), thus when to commit APP-directed treatment in DS need extensive clinical trials. HSA21 owns more than 200 protein-coding genes (Antonarakis et al., 2020). APP exerts significant effects on the transcription of multiple genes in human DS PSC-Derived neurons (Ovchinnikov et al., 2018). Although APP has been proven to have an important role in driving AD-like pathologies in DS, other gene products may also have impact on the pathogenesis of AD in DS with varying degrees. Indeed, normalizing App gene dose in Ts65Dn mouse (Ts65DnAPPfl/fl+) only partially rescued the deficits in retrograde axonal transport of neurotrophic signals (Salehi et al., 2006, Chen et al., 2020), implying that other genes beyond APP may also contribute to this specific pathology. It should also be noted that although we failed to find any effect of Posiphen on the expression of other proteins, the potential off-targeting effects of Posiphen can be limited by drug modification/optimization or by replaced by a more specific strategy like ASO as mentioned above.

Although APP gene dose has been argued not to contribute to tau pathology in human DS iPSC-derived cortical neurons (Ovchinnikov et al., 2018), we have found that Posiphen not only reduced APP/CTF/Ab, but also decreased the levels of phosphorylated tau in aged Ts65Dn mice (Chen et al., 2020). Like AD, DS also develops different neuropathologies including inflammation at different stages, thus combined treatments against different pathologies to combat AD in DS can be considered in both preclinical studies and clinical trials.

The author thanks Professor William C. Mobley (Department of Neurosciences, University of California San Diego) for guidance and all the authors are contributed in this project.

Xu-Qiao Chen*
Department of Neurosciences, University of California San Diego and for guidance and all the colleagues contributing to this project.

Xu-Qiao Chen*
Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.

*Correspondence to: Xu-Qiao Chen, PhD, qochen@ucsd.edu. https://orcid.org/0000-0001-7999-7246

January 15, 2021

Date of submission: November 30, 2020

Date of decision: January 15, 2021

Date of acceptance: February 8, 2021

Date of web publication: April 23, 2021

https://doi.org/10.4103/1673-5374.313044

How to cite this article: Chen XQ (2021) A pilot exploration with Posiphen to normalize amyloid precursor protein in Down syndrome. Neural Regen Res 16(12):2420-2421.

Copyright license agreement: The Copyright License Agreement has been signed by the author before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References
Antonarakis SE, Skotko BG, Rafii MS, Styrdum A, Pape SE, Bianchi DW, Sherman SL, Reeves RH (2020) Down syndrome. Nat Rev Dis Primers 6:9.

Chen XQ, Mobley WC (2019a) Alzheimer disease: pathogenesis: insights from mouse and cellular biology studies of oligomeric Abeta and Tau species. Front Neurosci 13:659.

Chen XQ, Mobley WC (2019b) Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: converging insights from alternative hypotheses. Front Neurosci 13:446.

Chen XQ, Salehi A, Pearn ML, Overk C, Nguyen PD, Kleschevnikov AM, Macccecin M, Mobley WC (2020) Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its processing products reverse endosomal phenotypes in the Ts65Dn mouse model. Alzheimers Dement. doi: 10.1002/adb.12185.

Doran E, Keator D, Head E, Phelan MJ, Kim R, Totoiu M, Barrio JR, Small GW, Potkin SG, Lott IT (2017) Down syndrome, partial Trisomy 21, and absence of Alzheimer’s Disease: the role of APP. J Alzheimers Dis 56:459-470.

Jiang Y, Sato Y, Im E, Berg M, Bordi M, Darij S, Kumar A, Mohan PS, Bandopadhyay U, Diaz A, Cuervo AM, Nixon RA (2019) Neuronal dysfunction in Down syndrome is APP-dependent and mediated by APP-betaCTF (C99). J Neurosci 39:5255-5268.

Leavitt BR, Tabrizi SJ (2020) Antisense oligonucleotides for neurodegeneration. Science 367:1428-1429.

Macccecin M, Chang MY, Pan C, John V, Zetterberg H, Hung NH (2013) Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetic humans. J Neurol Neurosurg Psychiatry 83:894-902.

Nixon RA (2017) Amyloid precursor protein and endosomal/luminal dysfunction in Alzheimer’s disease: inseparable partners in a multifactorial disease. FASEB J 31:2729-2743.

Ovchinnikov DA, Korn O, Virshup I, Wells CA, Wolvetang EJ (2018) The impact of APP on Alzheimer-like pathogenesis and gene expression in Down syndrome iPSC-derived neurons. Stem Cell Reports 11:32-42.

Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC (1998) Molecular mapping of Alzheimer-type dementia in Down’s syndrome. Ann Neurol 43:380-383.

Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kalnins LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC (2006) Increased expression in Down syndrome. Nat Rev Dis Primers 6:9.

Saito M, Oinuma S, Utsuki T, Padmaraju V, Mazell C, Tzekou A, Sambamurti K, Arancio O, Macccecin M (2018) Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. Alzheimers Dement (NY) 4:37-49.

Xu W, Weissmiller AM, White JA, 2nd, Fang F, Wang X, Yu P, Pearn ML, Zhao X, Sawa M, Chen S, Gunawardena S, Chesson A, Utsuki T, Padmaraju V, Mazell C, Tzekou A, Sambamurti K, Arancio O, Macccecin M (2018) Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. Alzheimers Dement (NY) 4:37-49.

Xu W, Weissmiller AM, White JA, 2nd, Fang F, Wang X, Yu P, Pearn ML, Zhao X, Sawa M, Chen S, Gunawardena S, Chesson A, Utsuki T, Padmaraju V, Mazell C, Tzekou A, Sambamurti K, Arancio O, Macccecin M (2018) Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. Alzheimers Dement (NY) 4:37-49.